Odyssey Therapeutics, Inc. (NasdaqCM: ODTX)
Health Care · Biotechnology · US
$25.10
+21.08% today · +26.2% 1Y
Odyssey Therapeutics, Inc. (NasdaqCM: ODTX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $993.35M and employs 100 people.
Over the last twelve months the share price has gained 26.2%, trading between 15.10 and 22.26.
Tweenvest scores Odyssey Therapeutics, Inc. across four factors: quality 26/100. Its strongest factor is quality.
ODTX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $993.35M
- Revenue (TTM)
- $99.00K
- P/E
- —
- EPS
- -14.05
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $22.26
- 52-week low
- $15.10
- Avg volume (3M)
- —
- Shares outstanding
- 47.92M
- Employees
- 100
- Next earnings
- —
About Odyssey Therapeutics, Inc.
Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on discovering and developing novel treatments for autoimmune and inflammatory diseases. Its diverse pipeline features several key drug candidates: OD-001, an oral small molecule that inhibits receptor-interacting protein kinase 2, which is currently in Phase 2a clinical trials for ulcerative colitis. Also included is OD-002, an oral small molecule SLC15A4 inhibitor engineered to prevent harmful inflammatory responses driven by TLR7/8/9-mediated activation of interferon regulatory factor 5 (IRF5). Another program, OD-003, is a protein therapeutic designed to selectively agonize tumor necrosis factor receptor 2 on T regulatory cells. Further assets in its portfolio comprise a bispecific antagonist targeting TSLP and IL-33, an oral small molecule functioning as an interleukin-1 receptor-associated kinase 4 scaffolding inhibitor, and a separate small molecule inhibitor specifically targeting IRF5. The company was founded in 2021 and is headquartered in Boston, Massachusetts.
- ISIN
- US67613T1043
- Founded
- 2021
- Listed since
- May 8, 2026
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $260.63 | -1.94% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $438.87 | -0.76% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.49 | -0.19% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $550.54 | -0.42% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $819.48 | -1.69% |
| argenx SEENXTBR: ARGX | $64.17B | €900.00 | +2.37% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $147.14 | -7.36% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.